The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Using CRISPR technology to identify genes preferentially essential for multiple myeloma cells
Constantine Mitsiades, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses a study which used CRISPR technology to characterize and understand which genes are essential for multiple myeloma cells. Dr Mitsiades highlights the value of this work and explains how this information may be used to identify new therapeutic targets. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
